1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap

 
• By Sukaina Virji

Sanofi and Boehringer Ingelheim are in exclusive negotiations to swap parts of their businesses. The deal would involve an exchange of Sanofi's animal health business Merial, which is worth €11.4bn, with Boehringer's consumer healthcare (CHC) business, worth €6.7bn. To make up the difference in value between the two businesses, Boehringer would make a cash payment to Sanofi of €4.7bn.

Sanofi and Boehringer Ingelheim are in exclusive negotiations to swap parts of their businesses. The deal would involve an exchange of Sanofi's animal health business Merial, which is worth €11.4bn, with Boehringer's consumer healthcare (CHC) business, worth €6.7bn. To make up the difference in value between the two businesses, Boehringer would make a cash payment to Sanofi of €4.7bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss

 
• By Alaric DeArment

The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.

More from Therapy Areas

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 
• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.